Increasing the density of the D 2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 1, 2012, Pages 60-70

  Koener, Beryl ^a   Focant, Marylène C ^a   Bosier, Barbara ^a   Maloteaux, Jean Marie ^a   Hermans, Emmanuel ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

( ) 3 PPP; G protein; Inducible expression; N methyl d glucamine

Indexed keywords

ARIPIPRAZOLE; BUTYRIC ACID; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE D2L RECEPTOR; DOXYCYCLINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; HALOPERIDOL; MEGLUMINE; PRECLAMOL; UNCLASSIFIED DRUG; LIGAND; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DENSITY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; HELA CELL; METABOLISM; MOUSE; PARTIAL AGONISM; PHYSIOLOGY;

ANIMALS; DRUG PARTIAL AGONISM; HELA CELLS; HUMANS; LIGANDS; MICE; PIPERAZINES; PROTEIN BINDING; QUINOLONES; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION;

EID: 82555167016     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.08.007     Document Type: Article

References (47)

1. Bardin L., Kleven M.S., Barret-Grevoz C., Depoortere R., Newman-Tancredi A. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 2006, 31:1869-1879.
2. Bosier B., Hermans E. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. Trends Pharmacol Sci 2007, 28:438-446.
3. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002, 302:381-389.
4. Cook B.L., Ernberg K.E., Chung H., Zhang S. Study of a synthetic human olfactory receptor 17-4: expression and purification from an inducible mammalian cell line. PLoS One 2008, 3:e2920.
5. Cordeaux Y., Nickolls S.A., Flood L.A., Graber S.G., Strange P.G. Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype. J Biol Chem 2001, 276:28667-28675.
6. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
7. + modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists. Eur J Pharmacol 2004, 494:121-130.
8. Gardner B., Hall D.A., Strange P.G. Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells. Br J Pharmacol 1996, 118:1544-1550.
9. Gazi L., Bobirnac I., Danzeisen M., Schupbach E., Langenegger D., Sommer B., et al. Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells. Br J Pharmacol 1999, 128:613-620.
10. Geurts M., Hermans E., Maloteaux J.M. Enhanced striatal dopamine D(2) receptor-induced [35S] GTPgammaS binding after haloperidol treatment. Eur J Pharmacol 1999, 382:119-127.
11. Guiramand J., Montmayeur J.P., Ceraline J., Bhatia M., Borrelli E. Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J Biol Chem 1995, 270:7354-7358.
12. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 2003, 99:25-44.
13. Hermans E., Challiss R.A., Nahorski S.R. Effects of varying the expression level of recombinant human mGlu1alpha receptors on the pharmacological properties of agonists and antagonists. Br J Pharmacol 1999, 126:873-882.
14. Jerman J.C., Brough S.J., Gager T., Wood M., Coldwell M.C., Smart D., et al. Pharmacological characterisation of human 5-HT2 receptor subtypes. Eur J Pharmacol 2001, 414:23-30.
15. Jordan S., Johnson J.L., Regardie K., Chen R., Koprivica V., Tadori Y., et al. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:348-356.
16. Kapur S., Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001, 158:360-369.
17. Kenakin T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 1997, 18:456-464.
18. Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995, 274:329-336.
19. Kilts J.D., Connery H.S., Arrington E.G., Lewis M.M., Lawler C.P., Oxford G.S., et al. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 2002, 301:1179-1189.
20. Kiss B., Horvath A., Nemethy Z., Schmidt E., Laszlovszky I., Bugovics G., et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010, 333:328-340.
21. Koener B., Goursaud S., Van De S.M., Calas A.G., Jeanjean A.P., Maloteaux J.M., et al. Pharmacological blockade of dopamine D receptors by aripiprazole is not associated with striatal sensitization. Naunyn Schmiedebergs Arch Pharmacol 2011, 383:65-77.
22. Lane J.R., Powney B., Wise A., Rees S., Milligan G. Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1, Gi2, and Gi3. Mol Pharmacol 2007, 71:1349-1359.
23. Lane J.R., Powney B., Wise A., Rees S., Milligan G. G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors. J Pharmacol Exp Ther 2008, 325:319-330.
24. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20:612-627.
25. Lin H., Saisch S.G., Strange P.G. Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor. Br J Pharmacol 2006, 149:291-299.
26. Meller E., Helmer-Matyjek E., Bohmaker K., Adler C.H., Friedhoff A.J., Goldstein M. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur J Pharmacol 1986, 123:311-314.
27. Momiyama T., Amano T., Todo N., Sasa M. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol 1996, 310:1-8.
28. Mottola D.M., Kilts J.D., Lewis M.M., Connery H.S., Walker Q.D., Jones S.R., et al. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 2002, 301:1166-1178.
29. Neve K.A. Regulation of dopamine D2 receptors by sodium and pH. Mol Pharmacol 1991, 39:570-578.
30. Neve K.A., Cumbay M.G., Thompson K.R., Yang R., Buck D.C., Watts V.J., et al. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol Pharmacol 2001, 60:373-381.
31. Nickolls S.A., Strange P.G. Interaction of the D2short dopamine receptor with G proteins: analysis of receptor/G protein selectivity. Biochem Pharmacol 2003, 65:1139-1150.
32. Nickolls S.A., Strange P.G. The influence of G protein subtype on agonist action at D2 dopamine receptors. Neuropharmacology 2004, 47:860-872.
33. Pihlavisto M., Sjoholm B., Scheinin M., Wurster S. Modulation of agonist binding to recombinant human alpha2-adrenoceptors by sodium ions. Biochim Biophys Acta 1998, 1448:135-146.
34. Reeves P.J., Kim J.M., Khorana H.G. Structure and function in rhodopsin: a tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants. Proc Natl Acad Sci U S A 2002, 99:13413-13418.
35. Schnell D., Seifert R. Modulation of histamine H(3) receptor function by monovalent ions. Neurosci Lett 2010, 472:114-118.
36. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2 (high) receptors. CNS Neurosci Ther 2011, 17:118-132.
37. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719.
38. Selent J., Sanz F., Pastor M., De Fabritiis G. Induced effects of sodium ions on dopaminergic G-protein coupled receptors. PLoS Comput Biol 2010, 6.
39. Selley D.E., Cao C.C., Liu Q., Childers S.R. Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus. Br J Pharmacol 2000, 130:987-996.
40. Semba J., Watanabe A., Kito S., Toru M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 1995, 34:785-791.
41. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
42. Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 2005, 515:10-19.
43. Tadori Y., Forbes R.A., McQuade R.D., Kikuchi T. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol 2009, 607:35-40.
44. Tamminga C.A., Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002, 1:141-147.
45. Urban J.D., Vargas G.A., von Zastrow M., Mailman R.B. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007, 32:67-77.
46. Watts V.J., Lawler C.P., Gonzales A.J., Zhou Q.Y., Civelli O., Nichols D.E., et al. Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists. Synapse 1995, 21:177-187.
47. Yokoo H., Goldstein M., Meller E. Receptor reserve at striatal dopamine receptors modulating the release of [3H] dopamine. Eur J Pharmacol 1988, 155:323-327.